Skip to main content

Two Risperdal Cases Allowed To Seek Punitive Damages

Two Risperdal Cases Allowed To Seek Punitive Damages

Two Risperdal Cases Allowed To Seek Punitive Damages

Introduction

Judge Arnold New on Friday allowed two boys to pursue punitive damages linked to their claims against Johnson & Johnson unit that they were not given an appropriate warning about the alleged breast growth due to Risperdal consumption.

The Pennsylvania judge also rejected arguments by Janssen Pharmaceuticals Inc. (a subsidiary of J&J) in the Philadelphia County Court of Common Pleas to permit the statutory protections against punitive damages, a privilege offered under New Jersey law to avoid the chance of any additional payouts. Risperdal is an antipsychotic drug used to treat depressive symptoms. However, lawsuits filed across the nation claim the prolonged use of the medication caused gynecomastia or enlargement of male breasts, often requiring a correction surgery. More than 7,000 product liability lawsuits have been filed against J&J and Janssen Inc. for failing to provide adequate warning to consumers regarding the adverse effects of the drug. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!